There has been a recent shortage of a number of menopausal hormone therapy (MHT) preparations and some of these have now been or soon will be resolved:
Oral MHT
Duavive – supply due to be resolved by end January 2022
Progynova 2mg – supply due to be resolved by end of April 2022
Femonston Conti – supply shortage expected between 25 June and 9 July
Transdermal MHT
Estradot 100 – supply due to be resolved by 31 August
Estradot 75 – supply due to be resolved by 31 August
Estradot 50 – supply due to be resolved by 1 July
Estradot 37.5 – supply due to be resolved by 31 August
Estradot 25 – supply due to be resolved by 1 July
Estalis Conti 50/140 – supply resolved
Estalis Conti 50/250 – supply resolved
Estalis Sequi 50/140 – supply resolved
Estalis Sequi 50/250 – supply resolved
Estraderm MX 50 – supply resolved
Estraderm MX 100 - supply resolved
Non-Hormonal Options
There is also an expected shortage of supply of non-hormonal treatment options:
Gabapentin-APOTEX 100mg – supply shortage expected between 20 August- 15 October
Gabapentin 300mg- supply shortage expected between 18 June- 16 July
APX-Gabapentin 300mg- supply shortage expected between 16 July- 6 August
Gabapentin-APOTEX 300mg – to be discontinued from 18 July
Combined oral contraceptive pill
There is also an expected shortage of combined oral contraceptive pill:
Qliara – supply due to be resolved by 1 June 2022
Please note that dates for supply have been sourced from either the pharmaceutical supplier or the TGA website and may change at any time.
Content updated 23 June 2021
